Privacy Policy 2017-07-27T10:02:26-04:00

Stallergenes Greer Web Site Privacy Policy for

This Privacy Policy (the “Policy”) describes how we at Stallergenes Greer handle information collected from users of the website (the “Site”). We want to be sure you understand our practices and how we strive to protect personal information collected by the Site. By using the Site, you agree to the terms of this Privacy Policy, so please do not use the Site if you do not agree with these terms.

We may update this Privacy Policy at any time. Any changes to the Policy will become effective upon the date of our posting of the revised Policy on the Site. If you use the Site following the effective date of the revised Policy, you will be deemed to have accepted the Policy’s updated terms.

  1. What Types of Information Do We Collect Through the Site?
    The information we collect through the Site includes “Personally Identifiable Information” (or “PII”), which is information that identifies you personally, such as your first and last name, postal address, email address, date of birth, and telephone number. We collect this information when you voluntarily provide it to us, such as when you enroll in the All-Points AllergyTM program or send us an e-mail containing personal information, including your e-mail address. 
The Site also automatically collects information about you that is not PII but relates to your use of the Site. Non-PII is aggregated information, demographic information and any other information that does not reveal your specific identity. Non-PII is “passively” collected from you through browser navigational tools, such as cookies, that identify you only by your IP address — the Internet Protocol address of the computer that you use to access the Site. These types of technologies enable the Site to compile statistics about our daily number of Site visitors or specific page requests. We track usage patterns on our Web site and break down overall usage statistics according to a user’s domain name, browser type, and MIME type by reading this information from the browser string (information contained in every user’s browser).
A cookie is a small data file that a Web site transfers to a user’s hard drive when a user visits the Web site. A cookie file can contain information such as a unique ID that the site uses to track the pages visited. You can set your browser to accept all cookies, to reject all cookies, or to notify you whenever a cookie is offered so that you can decide each time whether to accept it. However, refusing a cookie may in some cases preclude you from using, or negatively affect the display or function of, the Site or certain areas or features of the Site. To learn more about cookies, please visit 
By using the Site, you are deemed to unambiguously agree to its use of any cookies that you do not disable.
  2. How Does Stallergenes Greer Use the Information It Collects?
    1. We may use the PII that we collect for any or all of the following purposes:
      1. Fulfillment of Requests. We may use PII about you to fulfill your requests, such as to send you information for the All-Points Allergy program.
      2. Administrative Communications. We may use your PII to send you important information, such as changes to our terms, conditions, and policies and/or other administrative information. Because this information may be important, you may not opt out of receiving such communications.
      3. Other Communications. We may use your PII to inform you of products, programs, services and surveys that we believe may be of interest to you. You may opt out of receiving such communications, as described in Section 4 (“Choices”) below.
      4. Internal Business Purposes. We may also use PII about you for our internal business purposes, such as data and Site usage analysis, audits, developing new products, enhancing the design and functionality of the Site, improving our services, and determining the effectiveness of our promotional campaigns.
    2. Other Information. We use non-PII to help us improve the Site, such as by analyzing Site visitor trends, including usage of certain pages or functions on the Site. We may also use non-PII for other purposes, but if any such use involved combining the non-PII with any data so that it became identifiable to you or another person, we would then treat it as PII in accordance with this Policy.
  3. With Whom Does Stallergenes Greer Share PII Collected Through the Site?
    1. Operational Partners and Third Party Service Providers. We may share PII with unaffiliated third parties who provide us with services, such as the designer of the Site and others who assist us with technology, data analysis, or similar services. We do not share PII with unaffiliated third parties for their own marketing purposes.
    2. Acquirers or Assignees. In the event of any reorganization, merger, sale, joint venture, assignment, transfer or other disposition of all or any portion of Stallergenes Greer or its assets, we may transfer any and all information that we collect from Site users to the acquiring party or assignee.
    3. Entities Entitled Under Law. We may disclose PII we collect about you to others as we believe to be appropriate in the following circumstances: (i) when required by applicable law, including laws outside your country of residence; (ii) to comply with legal process; (iii) to respond to requests from public and government authorities; (iv) to enforce the terms and conditions for use of the Site, including this Privacy Policy; (v) to protect and defend our rights and property; (vi) to protect the interests and safety of Stallergenes Greer or others; and (vii) to permit us to pursue available remedies or limit the damages that we may sustain. We have no obligation to notify you of such disclosures, except as required by applicable law.
  4. How Can You Manage PII That We Maintain?
    1. Updating or Correcting PII. Consumers (patients): If you would like to correct or update PII you previously provided to us when enrolling in the All-Points Allergy program, you may submit a new enrollment form at any time. You may also unsubscribe from future communications through this Site. Healthcare professionals: To correct, remove or update PII you previously provided, please contact Stallergenes Greer as directed in Section 9 below (“Contacting Us”). For your protection, we may need to verify your identity before implementing your request. Please note that we are not responsible for correcting, updating or deleting any information in the databases of third parties.
  5. How Does Stallergenes Greer Protect and Maintain PII Collected Through the Site?
    1. Security. We use reasonable organizational, technical and administrative measures to help protect against the loss, misuse and alteration of the information under our control. However, no data transmission over the Internet or data storage system can be guaranteed to be 100 percent secure. You should be mindful of security risks whenever you electronically transmit information you consider confidential.
    2. Data Integrity and Retention. We will retain PII about you for the period necessary to fulfill the purposes outlined in this Policy or GREER’s data retention policies unless a longer retention period is required by law.
    3. Other Websites. The Site may contain links to websites operated by parties not affiliated with GREER. These linked sites are not under GREER’s control and we are not responsible for the privacy practices or the contents of any such unaffiliated parties or their websites. If you provide any PII through any such third-party website, your transaction will occur on such third party’s website (not this Site) and the PII you provide will be collected by, and controlled by the privacy policy of, that third party. We recommend that you familiarize yourself with the privacy policies and practices of any such third parties, which are not governed by this Privacy Policy.
  6. Collection of PII by Others Through Our Site. We do not allow others to collect the PII of visitors to our Site by tracking the usage of either our Site or other websites.
  7. Use of the Site by Children. This Site is not directed to children under the age of thirteen (13), and we do not knowingly collect PII from any children under age 13. If you are under age 13, please do not submit any PII to us.
  8. International Transfers of Information. By using the Site, you are deemed to understand and unambiguously consent to the collection and processing of your PII in the United States, with the awareness that the laws of the United States may not provide as much protection for PII as the laws of certain other countries or territories.
  9. Contacting Us. If you have any questions or concerns related to this Privacy Policy or the information practices of this Site, you may contact us:
    1. By e-mail:
    2. By phone: 800.378.3906 (between 8:30 am and 5:00 pm EST)
    3. By mail: GREER Laboratories, Inc. PO Box 800 Lenoir, NC 28645
Back to top

Initiate treatment with ORALAIR 4 months before the expected onset of each grass pollen season and maintain it throughout the grass pollen season.1

Indications and Usage

ORALAIR is an allergen extract indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for any of the 5 grass species contained in this product. ORALAIR is approved for use in persons 5 through 65 years of age.

ORALAIR is not indicated for the immediate relief of allergy symptoms.

Important Safety Information


  • ORALAIR can cause life-threatening allergic reactions such as anaphylaxis and severe laryngopharyngeal edema.
  • Do not administer ORALAIR to patients with severe, unstable or uncontrolled asthma.
  • Observe patients in the office for at least 30 minutes following the initial dose.
  • Prescribe auto-injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use.
  • ORALAIR may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction.
  • ORALAIR may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.

ORALAIR is contraindicated in patients with severe, unstable or uncontrolled asthma, patients with a history of any severe systemic allergic reaction or severe local reaction to sublingual allergen immunotherapy or of eosinophilic esophagitis, or patients who are hypersensitive to any of the inactive ingredients.

ORALAIR can cause systemic allergic reactions, including anaphylaxis, and severe local reactions, including laryngopharyngeal swelling, which may be life-threatening. Severe and serious allergic reactions may require treatment with epinephrine. Patients who have a systemic allergic reaction to ORALAIR should stop taking the product. Eosinophilic esophagitis has been reported in association with sublingual tablet immunotherapy. Discontinue ORALAIR in patients with persistent symptoms of eosinophilic esophagitis, including dysphagia or chest pain. ORALAIR treatment should be withheld if the patient is experiencing an acute asthma exacerbation. Re-evaluate patients who have recurrent asthma exacerbations and consider discontinuation of ORALAIR. Concomitant dosing with other allergen immunotherapy may increase the likelihood of local or systemic adverse reactions to either subcutaneous or sublingual allergen immunotherapy.

In case of oral inflammation or wounds, such as following oral surgery or dental extraction, ORALAIR treatment should be discontinued to allow complete healing of the oral cavity. The risk of ORALAIR may be increased when treatment is initiated during the grass pollen season.

The most common adverse events reported in ≥5% of patients were oral pruritus, throat irritation, ear pruritus, mouth edema, tongue pruritus, cough, and oropharyngeal pain. Patients who have escalating or persistent local reactions to ORALAIR should be reevaluated and considered for discontinuation of ORALAIR.

ORALAIR should be used during pregnancy or breastfeeding only if clearly needed.

Please click here for full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or

All material and content herein Copyright © 2018 Stallergenes Greer S.A. Inc. No material from this Web site may be used, reproduced, or copied in whole or in part without prior written permission from Stallergenes Greer S.A. All Rights Reserved Worldwide.
ORALAIR® is a registered trademark of Stallergenes Greer or its affiliates.
Allergy Perspectives is a registered trademark of Stallergenes Greer or its affiliates.
CoverMyMeds® is a registered trademark of CoverMyMeds LLC.
HubExpressSM is a service mark of CoverMyMeds LLC.
Stallergenes Greer Inc. 55 Cambridge Parkway, Suite 400, Cambridge, MA 02142
© Stallergenes Greer 2018. All Rights Reserved.